Trial Profile
Gene-transfer, Open-label, Dose-escalation Study of SPK-8011 [Adeno-associated Viral Vector With B-domain Deleted Human Factor VIII Gene] in Individuals With Hemophilia A
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Dirloctocogene samoparvovec (Primary) ; Azathioprine; Corticosteroid; Mycophenolate mofetil; Tacrolimus
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
- Sponsors Spark Therapeutics
- 08 Jan 2024 Status changed from active, no longer recruiting to completed.
- 29 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 21 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.